title: Phase II trial of cisplatin and alpha-interferon in advanced malignant melanoma.
abstract: OBJECTIVE
  To evaluate the antitumor activity of combination cisplatin (CDDP) and alpha-interferon (alpha-IFN) in advanced, measurable metastatic melanoma.
  
  
  METHODS
  Adult patients with metastatic melanoma were required to have bidimensionally measurable lesions and a Karnofsky performance status > or = 60%. Serum creatinine < or = to 1.5 mg/dL, creatinine clearance > or = 60 mL/min, adequate organ and bone marrow function, and radiologic proof of the absence of brain metastases were required. CDDP 40 mg/m2 intravenously (IV) on day 1 and day 8, and alpha-IFN 3 million units/m2 subcutaneously on days 1 to 5 and 8 to 12 were administered every 3 to 4 weeks.
  
  
  RESULTS
  Forty-two patients were entered onto this phase II trial and were assessable for response and toxicity. Three patients achieved complete responses (CRs) that lasted 31+, 5, and 8+ months. Seven patients had partial responses (PRs) and a median response duration of 4.4 months. The overall objective response rate was 24% (95% confidence interval, 12% to 39%). Toxicities were mild. Only 11% of the courses required dose reduction of alpha-IFN, and three of 128 courses required CDDP dose reduction for reversible nephrotoxicity.
  
  
  CONCLUSIONS
  The combination of moderate-dose CDDP and alpha-IFN as administered in this schedule is well tolerated and possesses encouraging activity in metastatic melanoma.
authors.affiliation: Department of Medical Oncology, City of Hope National Medical Center, Duarte, CA 91010-0269.
authors.forename: K A
authors.initials: KA
authors.lastname: Margolin
authors.forename: J H
authors.initials: JH
authors.lastname: Doroshow
authors.forename: S A
authors.initials: SA
authors.lastname: Akman
authors.forename: L A
authors.initials: LA
authors.lastname: Leong
authors.forename: R J
authors.initials: RJ
authors.lastname: Morgan
authors.forename: G
authors.initials: G
authors.lastname: Somlo
authors.forename: J
authors.initials: J
authors.lastname: Raschko
authors.forename: C
authors.initials: C
authors.lastname: Pereira
authors.forename: L
authors.initials: L
authors.lastname: Yonemoto
authors.forename: C
authors.initials: C
authors.lastname: Ahn
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D016898:Interferon-alpha / Q000008:administration & dosage; D008297:Male; D008545:Melanoma / Q000188:drug therapy* / Q000556:secondary; D008875:Middle Aged
chemical_list: D016898:Interferon-alpha; D002945:Cisplatin